Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo

BMC Pharmacology

Volumn 11, Issue , 2011, Pages

  Kudo, Chieko ^a   Yamakoshi, Hiroyuki ^a   Sato, Atsuko ^a   Nanjo, Hiroshi ^b   Ohori, Hisatsugu ^a   Ishioka, Chikashi ^a   Iwabuchi, Yoshiharu ^a   Shibata, Hiroyuki ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b AKITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; DEATH RECEPTOR 5; GO Y030; GO Y078; GO Y098; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; ALKADIENE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSACTIVATION; ANIMAL; APOPTOSIS; C57BL MOUSE; DRUG EFFECT; DRUG SCREENING; HUMAN; SOLUBILITY; SYNTHESIS; TUMOR CELL LINE;

ALKADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CURCUMIN; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, INBRED C57BL; SOLUBILITY;

EID: 79957533842     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-11-4     Document Type: Article

References (30)

1. Tan G, Gyllenhaal C, Soejarto DD. Biodiversity as a source of anticancer drugs. Curr Drug Targets 2006, 7:265-277. 10.2174/138945006776054942, 16515527.
2. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as Curecumin: from kitchen to clinic. Biochem Pharmacol 2008, 75:787-809. 10.1016/j.bcp.2007.08.016, 17900536.
3. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995, 270:24995-25000. 10.1074/jbc.270.42.24995, 7559628.
4. Surh YJ, Han SS, Keum YS, Seo HJ, Lee SS. Inhibitory effects of curcumin and capsaicin on phorbol ester-induced activation of eukaryotic transcription factors, NF-kappaB and AP-1. Biofactors 2000, 12:107-112. 10.1002/biof.5520120117, 11216470.
5. Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002, 21:8414-8427. 10.1038/sj.onc.1205947, 12466962.
6. Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Choi SH, Shim BS, Lee SH, Hong SI. Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol 2002, 21:379-383.
7. Hong RL, Spohn WH, Hung MC. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 1999, 5:1884-1891.
8. Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006, 26:85-90. 10.1161/01.ATV.0000191635.00744.b6, 16239599.
9. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000, 275:10405-10412. 10.1074/jbc.275.14.10405, 10744729.
10. Ryu MJ, Cho M, Song JY, Yun YS, Choi IW, Kim DE, Park BS, Oh S. Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 2008, 377:1304-1308. 10.1016/j.bbrc.2008.10.171, 19000900.
11. Hahm ER, Gho YS, Park S, Park C, Kim KW, Yang CH. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem Biophys Res Commun 2004, 321:337-344. 10.1016/j.bbrc.2004.06.119, 15358181.
12. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. Cancer Lett 1999, 141:159-165. 10.1016/S0304-3835(99)00098-1, 10454257.
13. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005, 14:120-125.
14. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10:6847-6854. 10.1158/1078-0432.CCR-04-0744, 15501961.
15. Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A, Takahashi S, Kato S, Suzuki T, Ishioka C, Iwabuchi Y, Shibata H. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006, 5:2563-2571. 10.1158/1535-7163.MCT-06-0174, 17041101.
16. Shibata H, Yamakoshi H, Sato A, Ohori H, Kakudo Y, Kudo C, Takahashi Y, Watanabe M, Takano H, Ishioka C, Noda T, Iwabuchi Y. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci 2009, 100:956-960. 10.1111/j.1349-7006.2009.01127.x, 19445025.
17. Yamakoshi H, Ohori H, Kudo C, Sato A, Kanoh N, Ishioka C, Shibata H, Iwabuchi Y. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorg Med Chem 2010, 18:1083-1092. 10.1016/j.bmc.2009.12.045, 20060305.
18. The Institute for Genomic Research (TIGR) TIGR was absorbed under the J. Craig Venter Institute name in 2007., The Institute for Genomic Research (TIGR)., http://www.tigr.org
19. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005, 65:2108-2114. 10.1158/0008-5472.CAN-04-2935, 15781620.
20. Hayashi M, Kamata E, Hirose A, Takahashi M, Morita T, Ema M. In silico assessment of chemical mutagenesis in comparison with results of Salmonella microsome assay on 909 chemicals. Mutat Res 2005, 588:129-135.
21. Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008, 7:163-173. 10.4161/cbt.7.2.5335, 18059181.
22. Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 2005, 26:1905-1913. 10.1093/carcin/bgi167, 15987718.
23. Lim JH, Park JW, Choi KS, Park YB, Kwon TK. Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells. Carcinogenesis 2009, 30:729-736. 10.1093/carcin/bgn265, 19037087.
24. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821. 10.1126/science.277.5327.818, 9242611.
25. Nakanishi H, Mochizuki Y, Kodera Y, Ito S, Yamamura Y, Ito K, Akiyama S, Nakao A, Tatematsu M. Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci 2003, 94:112-118. 10.1111/j.1349-7006.2003.tb01361.x, 12708484.
26. Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008, 52(Suppl 1):S103-127.
27. Das U, Sharma RK, Dimmock JR. 1,5-Diaryl-3-oxo-1,4-pentadienes: A case for antineoplastics with multiple targets. Current Medicinal Chemistry 2009, 16:2001-2020. 10.2174/092986709788682218, 19519378.
28. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2007, 30:85-94.
29. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344. 10.1038/nrc2106, 17457301.
30. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485. 10.1038/nrc2152, 17522716.